Company intelligence / Profile preview

Mustard Bio

Ownership: Private
Development stage: Other

Overview

Mustard Bio is a biotechnology company focused on developing next-generation cell therapies for cancer and autoimmune diseases. The company leverages a proprietary platform to engineer more durable and effective CAR-T cell therapies. Their approach aims to overcome common limitations of current cell therapies, such as exhaustion and limited persistence in the body. Mustard Bio is currently in the pre-clinical stage, advancing a pipeline of candidates targeting various hematological and solid tumor markers.

Therapeutic areas: ImmunologyOncology
Modalities: Cell therapyBiologicCAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Mustard Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mustard Bio.

Explore the full profile